A
Alcista
Alcista · 25%BMRN
$73.71
Precio del escenario
$55.140
+0.772 (+1.40%)Al cierre
Loading chart…
- Máximo
- 55.560
- Apertura
- 54.750
- Precio medio ponderado por volumen
- 55.05
- Volumen
- 1.85M
- Capitalización
- 15.85B
- Mínimo
- 54.460
- Importe
- 101.61M
- EV/EBITDA, TTM
- 12.60
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. Galafold (migalastat) is its oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease. Its portfolio also includes ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene.
Análisis de IA of BioMarin Pharmaceutical Inc. (BMRN)
MantenerCurrently, BioMarin Pharmaceutical Inc (BMRN) is not a strong buy due to its low RSI of 10.442, indicating it is oversold, but it also has a forward P/E of 9.3985, which suggests it may be undervalued. The recent negative performance, with a 20-day change of -16.57%, raises concerns, despite positive news regarding clinical trials that could support future growth.
Recomendaciones de analistas (24)
+58.41% de potencial alcista
Comprar
19 Comprar
5 Mantener
0 Vender
Actual: 55.14
Mínimo
60.00
Promedio
87.35
Máximo
120.00
BMO Capital
Superar al mercado
$97
2026-09-15
BMO Capital
2026-09-15
Precio objetivo
$97
Superar al mercado
Cantor Fitzgerald
Sobreponderar
$86
2026-09-01
Cantor Fitzgerald
2026-09-01
Precio objetivo
$86
Sobreponderar
Piper Sandler
Sobreponderar
$90
2026-09-01
Piper Sandler
2026-09-01
Precio objetivo
$90
Sobreponderar
H.C. Wainwright
Neutral
$60
2026-08-31
H.C. Wainwright
2026-08-31
Precio objetivo
$60
Neutral
Jefferies
Comprar
$105
2026-08-31
Jefferies
2026-08-31
Precio objetivo
$105
Comprar
Métricas de valoración
El PER previsto actual de BioMarin Pharmaceutical Inc. (BMRN) es 9.40, frente a su media de 5 años de 28.18.
Escenarios de precio de Alphio AI para BMRN
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con BMRN en cartera
Cronología de eventos
Noticias
8.510-09PRnewswireBioMarin Unveils New Data on VOXZOGO's Impact on Growth in Children
5.010-05PRnewswireBioMarin Appoints New Chief People Officer
2.010-02CNBCBioMarin Reports Five-Year Data on Pompe Disease Therapy
9.010-02NewsfilterBioMarin's Combination Therapy Shows Five-Year Efficacy in Pompe Disease
9.510-02PRnewswireLong-term Efficacy of POMBILITI + OPFOLDA in Late-Onset Pompe Disease
Preguntas frecuentes sobre BMRN, respondidas por Alphio AI
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. Galafold (migalastat) is its oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease. Its portfolio also includes ALE1, an oral small molecule for the potential treatment of hypophosphatasia (HPP), a rare genetic bone disease caused by mutations in the ALPL gene. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Currently, BioMarin Pharmaceutical Inc (BMRN) is not a strong buy due to its low RSI of 10.442, indicating it is oversold, but it also has a forward P/E of 9.3985, which suggests it may be undervalued. The recent negative performance, with a 20-day change of -16.57%, raises concerns, despite positive news regarding clinical trials that could support future growth.
24 analysts cover BMRN: 19 rate it Buy, 5 Hold and 0 Sell. The average price target is 87.35.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.